Volume 30, Issue 2 (Supplementary 2026)                   IBJ 2026, 30(2): 46-46 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Roshan M, Farnia P, Ghomi H R, Jafari S. Selective Anticancer Effects of Cold Atmospheric Pressure Plasma Via RONS-Mediated Redox Dysregulation in Lung Cancer Cells. IBJ 2026; 30 (2) :46-46
URL: http://ibj.pasteur.ac.ir/article-1-5549-en.html
Abstract:  
Introduction: Cold atmospheric plasma (CAP) acts as a redox-modulating anticancer modality by generating reactive oxygen and nitrogen species (RONS). This process elevates lipid peroxidation (measured as malondialdehyde [MDA]), suppress superoxide dismutase (SOD) activity, and trigger oxidative stress-driven apoptosis. The integrated assessment of RONS, MDA, and SOD delineates the mechanistic basis of CAP-induced redox disequilibrium and cytotoxicity in lung cancer cells.
Materials and Methods: Human and murine lung cancer cells were exposed to helium-based CAP at voltages of 4 kV and 6 kV for 180 s using a flexible microplasma jet. Analyses were performed 24 h after the treatment. CAP-induced oxidative stress was analyzed by quantifying intracellular RONS, MDA, and SOD activity, while cytotoxicity was evaluated using the MTT assay.
Results and Discussion: CAP treatment markedly modulated the intracellular redox status in a voltage-dependent manner. At 6 kV, levels of intracellular RONS and MDA increased significantly, while SOD activity and cell viability (as measured by the MTT assay) decreased compared to 4 kV treatment. This outcome indicates that higher voltage led to greater disruption and induces apoptosis.
Conclusion: CAP treatment at 6 kV induced a marked rise in intracellular RONS and MDA levels, with a concurrent decline in SOD activity and cell viability, indicating a severe redox imbalance and apoptosis induction compared to 4 kV treatment.

 
Type of Study: Congress | Subject: Related Fields

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb